

In the Claims:

Please amend the claims to read as follows (see Detail of claim amendments included):

543
in 3200
B4 Dina 1
1. (Twice Amended) A delivery device for treatment of erectile dysfunction in a patient, consisting of a disk of a filmogenic polymer, wherein the disk of filmogenic polymer contains an effective dose of a therapeutic agent suitable for treating erectile dysfunction.

2. (Twice Amended) A delivery device according to claim 1, comprising further at least one additive contained within the disk of filmogenic polymer, wherein the at least one additive is selected from the group consisting of a stabilizer, a solubilizer, an enhancer and a plasticizer.

B1
cont.
sub
D2
3. A delivery device according to claim 1, wherein the therapeutic agent is a prostaglandin.

4. A delivery agent according to claim 3, wherein the prostaglandin is prostaglandin E1.

5. A delivery device according to claim 1, wherein the therapeutic agent is selected from the group consisting of: a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α -blocker, and a calcium channel blocker.

6. A delivery device according to claim 5, comprising further at least an additional therapeutic agent.

543
D2
7. (Once Amended) A delivery device according to claim 6, wherein the at least additional therapeutic agent is selected from the group consisting of: prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a

minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxisylyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

8. (Once Amended) A delivery device according to claim 2, wherein the enhancer is at least one selected from the group consisting of a glycolipid, a non-esterified fatty acid, an aliphatic alcohol, a fatty acid ester of an aliphatic alcohol, a cyclohexanol, a fatty acid ester of glycerol, a glycol, an aliphatic alcohol ether of a glycol, and a surfactant.

9. (Once Amended) A delivery device according to claim 8, wherein the filmogenic polymer is polyvinyl pyrrolidone, the therapeutic agent is prostaglandin E1, the enhancer is hexyldecyl stearate, and the plasticizer is PEG 400.

B1
cont.
10. A delivery device according to claim 2, wherein the filmogenic material is present in an amount of 5 to 100%, the therapeutic agent is present in an amount of 0.1 to 20% w/w, the enhancer is present in an amount of 0.01 to 15%, and the plasticizer is present in an amount of 1 to 70%, each on a weight basis.

Cl. 11
was amended
but not
on marked
up copy
11. A delivery device according to claim 9, having polyvinyl pyrrolidone present in an amount that is 40 to 45%, having prostaglandin E1 present in an amount that is 5 to 10%, having Eutanol G16S present in an amount that is 1 to 4%, and having PEG 400 present in an amount that is 40 to 50%.

12. (Once Amended) A delivery device according to claim 9, having polyvinyl pyrrolidone present in an amount that is 40 to 45%, having prostaglandin E1 present in an amount that is 5 to 10%, having hexyldecyl stearate present in an amount that is 1 to 4%, and having PEG 400 present in an amount that is 40 to 50%.

13. A delivery device according to claim 1, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer.

- B1
cont.
14. A delivery device according to claim 13, wherein the synthetic polymer is polyvinyl pyrrolidone.
 15. A delivery device according to claim 13, wherein the naturally occurring polymer is from a plant.
 16. A delivery device according to claim 15, wherein the plant polymer is a gliadin.
 17. (Once Amended) A delivery device according to claim 2, having a plasticizer in an amount less than 30% on a dry weight basis.
 18. A delivery device according to claim 1, wherein delivery is transdermal.
 19. A delivery device according to claim 1, wherein delivery is transmucosal.
 20. A delivery device according to claim 1, wherein the effective dose is released into the subject within one hour.
 21. (Twice Amended) A method of treating erectile dysfunction, comprising:
 - selecting a device consisting of a disk of a filmogenic polymer; wherein the disk of filmogenic polymer contains at least one therapeutic agent suitable for treating erectile dysfunction;
 - wetting a penile surface; and
 - placing the device in contact with the wetted penile surface delivering the therapeutic agent to the penile surface over an effective period of time.
 22. (Once Amended) A method according to claim 21, wherein in forming the disk, the therapeutic agent is selected from the group consisting of a prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a sildenafil, a minoxidil, a

misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxislyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

23. A method according to claim 21, wherein the therapeutic agent is present in a range of 0.1-15%, on a dry weight basis.

24. A method according to claim 21, wherein forming the disk further comprises adding plasticizer.

25. A method according to claim 24, wherein the plasticizer is present in an amount that is less than 30% on a dry weight basis, and delivering the therapeutic agent to the penile surface has the additional step of pre-wetting the surface.

26. A method according to claim 24, wherein the plasticizer is a polyethylene glycol (PEG).

27. A method according to claim 26, wherein the PEG is PEG 400.

28. A method according to claim 27, wherein the synthetic polymer is synthetic polymer.

29. A method according to claim 28, wherein the synthetic polymer is polyvinyl pyrrolidone.

30. A method according to claim 29, wherein the filmogenic polymer is a plant protein.

31. A method according to claim 30, wherein the plant protein is a prolamine.

32. A method according to claim 31, wherein the prolamine is a gliadin.

Serial No.: 09/340,338
Group Art Unit: 1615

34. A method according to claim 21, wherein the effective period of time is 5-100 minutes.

*B2
concl*
35. A method according to claim 34, wherein the effective period of time is 30-60 minutes.

36. A method according to claim 21, wherein the penile surface is selected from the group consisting of the shaft and the glans.
